Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924493 | 0.90 | BACE1 (0.44) | BACE1CYP2C9CYP3A4ALDH1A1HPGD | |
| SCHEMBL925096 | 0.82 | KDM4E (0.41) | BACE1CYP2C9ALDH1A1HPGDCYP1A2 | |
| SCHEMBL4970599 | 0.77 | BACE1 (0.35) | BACE1CYP2C9CYP3A4 | |
| SCHEMBL926212 | 0.75 | HSD17B10 (0.43) | CYP2C9ALDH1A1HPGDCYP1A2CYP2D6 | |
| SCHEMBL924396 | 0.73 | LMNA (0.39) | ALDH1A1HPGDGAAHSD17B10HCAR3 | |
| SCHEMBL925194 | 0.71 | HSD17B10 (0.40) | ALDH1A1HPGDTP53GAAHSD17B10 | |
| SCHEMBL924196 | 0.71 | ALDH1A1 (0.54) | ALDH1A1HPGDGAAHSD17B10MEN1 | |
| SCHEMBL924275 | 0.71 | GAA (0.40) | ALDH1A1HPGDSMN1; SMN2GAAHSD17B10 | |
| SCHEMBL5217707 | 0.71 | ALDH1A1 (0.54) | CYP2C9CYP3A4ALDH1A1HPGDCYP1A2 | |
| SCHEMBL923798 | 0.69 | HSD17B10 (0.39) | ALDH1A1HPGDGAAHSD17B10HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163766-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7872009-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1954693-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007062007-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | BACE1 1/4885CYP2C9 3151/4885CYP3A4 2199/4885 |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | BACE1 1/4885CYP2C9 3151/4885CYP3A4 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.